Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety of malignancies. Sintilimab, a highly selective, fully human monoclonal antibody (mAb), blocks the interaction of PD-1 and its ligands and has demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jie, Fei, Keke, Jing, Hua, Wu, Zhihai, Wu, Weiwei, Zhou, Shuaixiang, Ni, Haiqing, Chen, Bingliang, Xiong, Yan, Liu, Yanpeng, Peng, Bo, Yu, Dechao, Jiang, Haiping, Liu, Junjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816392/
https://www.ncbi.nlm.nih.gov/pubmed/31402780
http://dx.doi.org/10.1080/19420862.2019.1654303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816392/
https://www.ncbi.nlm.nih.gov/pubmed/31402780
http://dx.doi.org/10.1080/19420862.2019.1654303

Ejemplares similares